"Together for Clear Vision, Shaping a Colorful Future": Shanghai Pharma Holdings and Novartis China Announce Strategic Collaboration on Ophthalmic Products

Leo Li, President and Managing Director of Novartis China, Chen Hui, Head of Retail, Emerging Markets and Commercial Operations at Novartis China, Richard Li, Executive Director and CEO of Shanghai Pharmaceuticals, Tang Pengcheng and Zhang Yan, Vice Presidents of Shanghai Pharmaceutical Co., Ltd., among other management representatives from both parties attended the ceremony.

As a strategic leader and pioneer in the field of ophthalmic treatment, Novartis China has relied on decades of profound accumulation and forward-looking layout. Guided by strategic vision, driven by technological innovation, and centered on patient needs, it has continuously focused on the two key areas of anti-infection and glaucoma. By building solutions that cover the entire disease process, Novartis has not only consolidated its leading position in the industry but also provided a strategic model and development momentum for the global ophthalmic medical advancement through innovative practices, leading the industry towards a new phase of high-quality development.

Shanghai Pharmaceutical Co.,Ltd. asThe Leading Technology-Driven Health Service Company in China, always adhering to compliant operations as the cornerstone of development, shaping competitive advantages through brand strategy, relying on systematic resource deployment and professional service capabilities to build a service matrix covering all scenarios in the pharmaceutical commerce sector, and continuously deepening"Innovative Practice of the 'Integrated General Contracting' Business Model." In the field of contract sales, Shanghai Pharmaceutical Co., Ltd. has successfully built a professional service network covering medical institutions and retail terminals across China after nearly 10 years of development.With strong channel integration and terminal coverage capabilities。

In recent years, ophthalmic diseases in China have shown significant changes, with a high incidence of ocular infectious diseases coexisting with the challenges of glaucoma prevention and treatment, posing dual challenges to patients' health and social medical resources. Against this backdrop, Shanghai Pharmaceutical Co., Ltd. and Novartis China have reached a strategic cooperation, precisely responding to the urgent market demand for high-quality eye health solutions.This not only marks a new height in the strategic layout of both parties in the ophthalmology field but also becomes an important milestone in driving industry transformation.

"Li Yao, President and Managing Director of Novartis China, said: “As a global leading innovative pharmaceutical company, Novartis has always adhered to the concept of 'Commitment to China'., committed to envisioning the future of medicine, improving people's quality of life, and extending human lifespan. Novartis continues to strengthen close collaboration with all parties in China's pharmaceutical supply chain, as exemplified by the anterior segment ophthalmology project we are conducting with Shanghai Pharmaceutical Co., Ltd.We hope to enhance the accessibility of Novartis' ophthalmology products in the Chinese market and continue to benefit more ophthalmology patients by leveraging Novartis' leadership in the ophthalmology field and integrating the resources and advantages of Shanghai Pharmaceutical Co., Ltd.Truly help improve the eye health level of the Chinese people.”

Li Yongzhong, Executive Director and Executive President of Shanghai Pharmaceuticals, stated: “Shanghai Pharmaceutical Co., Ltd. has always deeply embedded the concept of 'Service as Honor' within its core development. This strategic cooperation with Novartis China...Both parties will fully leverage the core advantages of Shanghai Pharmaceutical Co., Ltd. in channel management and terminal coverage. Through scientific supply chain integration and meticulous market layout, they will accelerate the extension of high-quality products such as Novartis China's ophthalmic drugs for the anterior segment to a broader market.", effectively improving the accessibility of medications for grassroots patients, demonstrating the shared pursuit and excellent practice of both parties in the cause of inclusive healthcare."

Company Profile